Brian Mitchell

Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO).

Cooley advised Baseten, a company powering inference for the world’s fastest-growing artificial intelligence products, on its $150 million Series D financing, valuing the company at $2.15 billion.

Cooley advised Wugen, a clinical-stage biotechnology company pioneering the next generation of allogeneic, off-the-shelf chimeric antigen receptor T-cell (CAR-T) therapies, on its $115 million Series C financing.

Cooley advised Ambiq Micro, a technology leader in ultra-low-power semiconductor solutions for edge artificial intelligence, on its $96 million initial public offering (IPO).